New management like to shake things up. The word from the chief executive’s office is always about “fresh departures” and “exciting horizons”. There might even be a tinkering with corporate strategy for good measure.

Yet when the dust settles, much ends up remaining the same. Large companies are sluggish, inflexible beasts when it comes to change. That’s why institutional, low-risk investors like them so much.

Enter Andrew Witty. The chief executive of UK-based pharmaceutical company GlaxoSmithKline has ditched the standard script. He’s about change, real change. After spending a few months settling in at the helm, Witty has now sent out signals that could radically alter Big Pharma.

Upcoming Ethical Corporation conferences & events:
Please login to view whole article - or subscribe here.

For a free two week trial to Ethical Corporation online, please click here.